Findell Capital Management LLC Buys Shares of 231,000 Vor Biopharma Inc. $VOR

Findell Capital Management LLC bought a new stake in shares of Vor Biopharma Inc. (NASDAQ:VOR) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 231,000 shares of the company’s stock, valued at approximately $3,021,000. Vor Biopharma comprises about 0.9% of Findell Capital Management LLC’s portfolio, making the stock its 14th biggest holding. Findell Capital Management LLC owned approximately 2.22% of Vor Biopharma as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. RA Capital Management L.P. increased its holdings in shares of Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. increased its holdings in shares of Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $33,275,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $22,890,000. Finally, NEXTBio Capital Management LP acquired a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $13,080,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on VOR shares. Wells Fargo & Company started coverage on Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Weiss Ratings cut Vor Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Finally, Wedbush increased their price target on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Vor Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director directly owned 4,555,741 shares in the company, valued at approximately $75,579,743.19. This represents a 11.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 3,002,903 shares of company stock valued at $49,412,176 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Vor Biopharma Trading Up 6.4%

Shares of Vor Biopharma stock opened at $15.02 on Thursday. Vor Biopharma Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $65.80. The stock has a 50 day moving average of $14.91 and a 200 day moving average of $14.08.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Research analysts predict that Vor Biopharma Inc. will post -2.51 earnings per share for the current year.

Vor Biopharma Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).